Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 4/20 | 0.40 |
| ▸ | FEN1 | P39748 | 4/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | CTSS | P25774 | 3/20 | 0.34 |
| ▸ | CTSK | P43235 | 3/20 | 0.34 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.34 |
| ▸ | HPGDS | O60760 | 2/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22384234 | 0.93 | LY96 (0.40) | ALOX5APFEN1TDP1LY96HPGDS | |
| SCHEMBL17834723 | 0.93 | LY96 (0.40) | ALOX5APFEN1TDP1LY96HPGDS | |
| SCHEMBL17825401 | 0.91 | MME (0.35) | ALOX5APFEN1HPGDSMME | |
| SCHEMBL22756207 | 0.90 | TDP1 (0.39) | TDP1CTSSCTSKLY96HPGDS | |
| SCHEMBL16305783 | 0.90 | TDP1 (0.39) | TDP1CTSSCTSKLY96HPGDS | |
| SCHEMBL17834699 | 0.89 | ALOX5AP (0.40) | ALOX5APFEN1TDP1CTSSCTSK | |
| SCHEMBL17834370 | 0.89 | TDP1 (0.36) | ALOX5APFEN1TDP1CTSSCTSK | |
| SCHEMBL17968845 | 0.87 | KIFC1 (0.41) | ALOX5APFEN1HPGDSMME | |
| SCHEMBL17825511 | 0.87 | KIFC1 (0.41) | ALOX5APFEN1HPGDSMME | |
| SCHEMBL22384245 | 0.86 | ALOX5AP (0.35) | ALOX5APFEN1MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3230276-B1 | GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-09-02 | — | — | EP | disclosed |
| US-10034886-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2018-07-31 | — | — | US | disclosed |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2018-01-25 | — | — | US | disclosed |
| US-9795613-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-10-24 | — | — | US | disclosed |
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-08-11 | — | — | US | disclosed |
| WO-2016094729-A1 | GLP-1 RECEPTOR MODULATORS | CELGENE INTERNATIONAL II SARL (CH) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | ALOX5AP 3115/4885FEN1 3722/4885TDP1 3121/4885 |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | ALOX5AP 3115/4885FEN1 3722/4885TDP1 3121/4885 |
| US-10034886-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | ALOX5AP 3438/4885FEN1 3634/4885TDP1 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.